Alcoholism - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 102

Alcoholism - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Alcoholism - Pipeline Review, Q2 2011', provides an overview of the Alcoholism therapeutic pipeline. This report provides information on the therapeutic development for Alcoholism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcoholism. 'Alcoholism - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Alcoholism.
- A review of the Alcoholism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alcoholism pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Alcoholism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alcoholism pipeline depth and focus of Alcoholism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcoholism Overview
Therapeutics Development
An Overview of Pipeline Products for Alcoholism
Alcoholism Therapeutics under Development by Companies
Alcoholism Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Alcoholism Therapeutics - Products under Development by Companies
Alcoholism Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Alcoholism Therapeutics Development
Eli Lilly and Company
GlaxoSmithKline plc
Alkermes, Inc.
Merck & Co., Inc.
Nippon Shinyaku Co., Ltd.
AEterna Zentaris Inc.
Catalyst Pharmaceutical Partners, Inc.
Biotie Therapies Corp.
Allon Therapeutics Inc.
Omeros Corporation
Alcoholism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nalmefene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OpRA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK598809 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALKS 33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALKS 29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEZS-123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-408 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topamax + Revia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zofran + Revia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tenex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prazosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inversine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mirtazapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chantix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zofran - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone + Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 900435 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zofran + ReVia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurontin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate + Yohimbine + Mcpp - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revia + Zoloft - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone + Disulfiram - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurontin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY686017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metadoxine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PPAR-Gamma Agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK561679 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone + Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cymbalta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quetiapine XR + Mirtazapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2196044 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lyrica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron + Topiramate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alcoholism Therapeutics – Drug Profile Updates
Alcoholism Therapeutics - Discontinued Products
Alcoholism - Featured News
Mar 29, 2011: Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients
Jan 03, 2011: Lundbeck Reports Positive Results From First Two Nalmefene Phase III Studies In Alcohol Dependence
Dec 08, 2010: Alkermes Announces Positive Phase II Study Results Of ALKS 33 In Alcohol Dependence
Jan 02, 2008: Nalmefene United Kingdom And Ireland Rights Acquired By Lundbeck
May 26, 2003: Merck KGaA Selects Nippon Shinyaku As Japanese Partner For Alcohol Addiction Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Alcoholism, Q2 2011
Products under Development for Alcoholism – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Alkermes, Inc., 2011
Merck & Co., Inc., 2011
Nippon Shinyaku Co., Ltd., 2011
AEterna Zentaris Inc., 2011
Catalyst Pharmaceutical Partners, Inc., 2011
Biotie Therapies Corp., 2011
Allon Therapeutics Inc., 2011
Omeros Corporation, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Alcoholism Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Alcoholism, Q2 2011
Products under Development for Alcoholism – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Alcoholism - Pipeline Review, Q4 2010
• Nausea - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Other Hematological Disorders - Pipeline Review, H2 2012
• Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2012
• Burns - Pipeline Review, H1 2013
• Neurofibromatoses - Pipeline Review, H2 2012
• Ageing - Pipeline Review, H2 2012
• Pandemic Influenza – Pipeline Review, H1 2013